Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ROGN.MX
- Price
- 7278.32
- Stock movement up
- +428.32 (6.25%)
- Company name
- Roche Holding AG
- Exchange
- (MX ,
- Currency
- MXN )
- Sector
- Healthcare >Drug Manufacturers - General
- Market cap
- 5019.32B
- Ent value
- 5073.49B
- Price/Sales
- -
- Price/Book
- 151.90
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -8.01%
- 1 year return
- 22.42%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-12-17
DIVIDENDS
ROGN.MX does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 151.90 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 689.63M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 7.55B |
| Net receivables | 11.92B |
| Total current assets | 35.70B |
| Goodwill | 7.57B |
| Intangible assets | 16.77B |
| Property, plant and equipment | 22.87B |
| Total assets | 94.77B |
| Accounts payable | 4.51B |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 27.58B |
| Total liabilities | 61.72B |
| Shareholder's equity | 33.04B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 7278.32 |
| Daily high | 7278.32 |
| Daily low | 7278.32 |
| Daily Volume | 0K |
| All-time high | 8906.23 |
| 1y analyst estimate | - |
| Beta | 0.17 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | 27 Mar 2025 |
| Next earnings date | 29 Jan 2026 |
Downside potential
Loading...
Downside potential data
| ROGN.MX | S&P500 | |
| Current price drop from All-time high | -18.28% | -1.22% |
| Highest price drop | -37.98% | -19.00% |
| Date of highest drop | 8 Jan 2025 | 8 Apr 2025 |
| Avg drop from high | -29.15% | -2.63% |
| Avg time to new high | - | 6 days |
| Max time to new high | 297 days | 89 days |
COMPANY DETAILS
Marketcap
5019.32B
Marketcap category
Large-cap
Description
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.
Employees
103249
Website
Investor relations
-
SEC filings
CEO
Country
Mexico
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
DelveInsight's Ulcerative Colitis Market Insights report includes a comprehensive understanding of current treatment practices, ulcerative colitis emerging drugs, market share of individual therapies,...
December 17, 2025
Hoffmann-La Roche Limited (Roche Canada) is proud to announce that Health Canada has granted market authorization for TNKase® (tenecteplase), a thrombolytic (clot-dissolving) agent, effective November...
December 17, 2025
AstraZeneca's Enhertu wins FDA nod as a first-line treatment for HER2-positive metastatic breast cancer.
December 16, 2025
Roche Holding (SWX:ROG) has been quietly rewarding patient shareholders, with the stock gaining about 12% over the past month and roughly 25% year to date, outpacing many large pharma peers. See our l...
December 16, 2025
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the new cobas® 6800/8800 systems version 2.0 and software version 2.0.1, following U.S. Food and Drug Administration (FDA) 510(k) clear...
December 16, 2025
OSLO, Norway & BOSTON, December 16, 2025--Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced th...
December 16, 2025
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved additional indications for its PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary An...
December 15, 2025
BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.
December 12, 2025
Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.
December 12, 2025
HOLX's Diagnostics gains accelerate as U.S. molecular testing drives growth and new Panther Fusion and Genius platform approvals widen its runway.
December 12, 2025
Next page